title: Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer.
abstract: Survivin is a member of the inhibitor of apoptosis protein (IAP) family containing a single baculovirus IAP repeat domain. It is expressed during fetal development but becomes undetectable in terminally differentiated normal adult tissues. We previously reported that survivin and its splicing variant survivin-2B was expressed abundantly in various types of tumor tissues as well as tumor cell lines and was suitable as a target antigen for active-specific anti-cancer immunization. Subsequently, we identified an HLA-A24-restricted antigenic peptide, survivin-2B80-88 (AYACNTSTL) recognized by CD8+ cytotoxic T lymphocytes (CTLs). We, therefore, started a phase I clinical study assessing the efficacy of survivin-2B peptide vaccination in patients with advanced or recurrent colorectal cancer expressing survivin. Vaccinations with survivin-2B peptide were given subcutaneously six times at 14-day intervals. Of 15 patients who finished receiving the vaccination schedule, three suffered slight toxicities, including anemia (grade 2), general malaise (grade 1), and fever (grade 1). No severe adverse events were observed in any patient. In 6 patients, tumor marker levels (CEA and CA19-9) decreased transiently during the period of vaccination. Slight reduction of the tumor volume was observed in one patient, which was considered a minor responder. No changes were noted in three patients while the remaining eleven patients experienced tumor progression. Analysis of peripheral blood lymphocytes of one patient using HLA-A24/peptide tetramers revealed an increase in peptide-specific CTL frequency from 0.09% to 0.35% of CD8+ T cells after 4 vaccinations. This phase I clinical study indicates that survivin-2B peptide-based vaccination is safe and should be further considered for potential immune and clinical efficacy in HLA-A24-expression patients with colorectal cancer.
authors.affiliation: Department of Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan. tsuruma@sapmed.ac.jp
authors.forename: Tetsuhiro
authors.initials: T
authors.lastname: Tsuruma
authors.forename: Fumitake
authors.initials: F
authors.lastname: Hata
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Torigoe
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Furuhata
authors.forename: Satomi
authors.initials: S
authors.lastname: Idenoue
authors.forename: Takehiro
authors.initials: T
authors.lastname: Kurotaki
authors.forename: Masaaki
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Atsuhito
authors.initials: A
authors.lastname: Yagihashi
authors.forename: Tosei
authors.initials: T
authors.lastname: Ohmura
authors.forename: Koji
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Tadashi
authors.initials: T
authors.lastname: Katsuramaki
authors.forename: Takahiro
authors.initials: T
authors.lastname: Yasoshima
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Sasaki
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Mizushima
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Minamida
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Kimura
authors.forename: Morifumi
authors.initials: M
authors.lastname: Akiyama
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Hirohashi
authors.forename: Hiroko
authors.initials: H
authors.lastname: Asanuma
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Tamura
authors.forename: Kumiko
authors.initials: K
authors.lastname: Shimozawa
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Sato
authors.forename: Koichi
authors.initials: K
authors.lastname: Hirata